Ken Frazier, Merck CEO (Andrew Harnik/AP Images)
April 29, 2021 11:21 AM EDT
Pharma

Ken Fra­zier ends his 29-year tenure at Mer­ck on a sour note, re­veal­ing a dip in sales in his fi­nal earn­ings call

Nicole DeFeudis

Editor

Af­ter 29 years at the com­pa­ny, Mer­ck CEO Ken Fra­zier is say­ing farewell on a sour note.

In his last-ever earn­ings call on Thurs­day morn­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times